WO2023078179A1 - Amorphous solid dispersion comprising (s) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1h-pyrazole-4-carboxamide - Google Patents

Amorphous solid dispersion comprising (s) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1h-pyrazole-4-carboxamide Download PDF

Info

Publication number
WO2023078179A1
WO2023078179A1 PCT/CN2022/128315 CN2022128315W WO2023078179A1 WO 2023078179 A1 WO2023078179 A1 WO 2023078179A1 CN 2022128315 W CN2022128315 W CN 2022128315W WO 2023078179 A1 WO2023078179 A1 WO 2023078179A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
asd
solid dispersion
amorphous solid
pharmaceutically acceptable
Prior art date
Application number
PCT/CN2022/128315
Other languages
French (fr)
Inventor
Xiangyang Chen
Original Assignee
Beijing Innocare Pharma Tech Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Innocare Pharma Tech Co., Ltd. filed Critical Beijing Innocare Pharma Tech Co., Ltd.
Priority to CA3235435A priority Critical patent/CA3235435A1/en
Publication of WO2023078179A1 publication Critical patent/WO2023078179A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Definitions

  • the present invention relates to amorphous solid dispersions of (S) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1H-pyrazole-4-carboxamide.
  • Compound I is a potent inhibitor of fibroblast growth factor receptors (FGFR) .
  • FGFR fibroblast growth factor receptors
  • FIG. 2 shows the DSC diagrams of amorphous solid dispersions made via spray drying.
  • FIG. 3 shows the DSC diagrams of amorphous solid dispersions made via hot melt extrusion.
  • FIG. 4 shows the XRPD diagrams of Type A and amorphous solid dispersions (HPMCAS) via made by spray drying.
  • FIG. 5 shows the XRPD diagrams of Type A and amorphous solid dispersions (PVPVA) made via hot melt extrusion.
  • FIG. 6 shows the XRPD diagrams of HPMCAS-10-SDD after storage under (A) 25°C/60%RH, sealed and (B) 40°C/75%RH, sealed.
  • FIG. 7 shows the XRPD diagrams of PVPVA-10-HME after storage under 25°C/60%RH, sealed.
  • FIG. 8 shows the DSC diagrams of HPMCAS-10-SDD after storage under (A) 25°C/60%RH, sealed and (B) 40°C/75%RH, sealed.
  • FIG. 9 shows the DSC diagrams of PVPVA-10-HME after storage under 25°C/60%RH, sealed.
  • FIG. 10 shows the solubility profiles of HPMCAS-10-SDD after storage under (A) 25°C/60%RH, sealed and (B) 40°C/75%RH, sealed.
  • FIG. 11 shows the solubility profiles of PVPVA-10-HME after storage under 25°C/60%RH, sealed.
  • the present invention is directed to an amorphous solid dispersion (ASD) comprising (S) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1H-pyrazole-4-carboxamide (Compound I) , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable polymer.
  • ASD amorphous solid dispersion
  • the present invention discloses that the ASD form of Compound I has advantages over the crystalline form for use in preparing drug formulations.
  • the ASD form of Compound I has good solubility and bioavailability, and is chemically and physically stable.
  • Type A crystalline form is prepared from Compound I as described in WO2018/049781.
  • Type A crystalline form can be prepared by dissolving Compound I in acetone/water, followed by precipitation at a lower temperature.
  • XRPD X-ray powder diffraction
  • Type A of the present invention has a solubility of 6.4 ⁇ g/mL after equilibrium in water at room temperature for 24 hours.
  • the ASD of Compound I comprises Compound I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable polymer.
  • the ASD of Compound I is stable in an amorphous form in a solid state for extended periods of time that may be used for preparing drug formulations.
  • the ASD of Compound I has a desirable pharmaceutical profile, and it is amenable to manufacturing.
  • a pharmaceutically acceptable polymer is included in ASD to stabilize the compound and the dispersion, which may be a hydrophilic polymer, including cellulose based polymers (e.g., hydroxypropylmethyl cellulose (HPMC, hypromellose) , ethyl cellulose, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hypromellose phthalate (HPMCP) , cellulose acetate, cellulose acetate phthalate, methyl cellulose, cellulose, carboxymethyl cellulose, microcrystalline cellulose, silicified microcrystalline cellulose, etc.
  • HPMC hydroxypropylmethyl cellulose
  • HPMCP hypromellose phthalate
  • starch based polymers e.g., hydroxypropyl starch, starches (including starches from any source, such as corn, potato, rice, wheat, which can be fully pregelatinized and partially gelatinized)
  • starch based polymers e.g., hydroxypropyl starch, starches (including starches from any source, such as corn, potato, rice, wheat, which can be fully pregelatinized and partially gelatinized)
  • polyethylene glycol polyacrylic acid, polyacrylamide, polyethylene oxide, polyvinylpyrrolidone, polyvinylalcohol, polyglycolized glycerides, polymethacrylates, hydrocolloids (e.g., carrageenan, chitosan, alginic acid, hyaluronic acid, pectinic acid, etc. ) .
  • Preferred polymers of the present invention include hydroxypropylmethylcellulose-acetate succinate (HPMC-AS) , polyvinylpyrrolidone-vinyl acetate copolymer (PVP-VA) , polyvinylpyrrolidone (PVP) , and hydroxypropylmethylcellulose (HPMC) .
  • HPMC-AS and PVP-VA are further preferred.
  • the amount of Compound I in ASD is in general 5-60%, or 5-50%, 5-40%, 10-50%, or 10-40%by weight.
  • the amount of Compound I in ASD (drug loading) is 10%or 20%by weight.
  • the weight ratio of Compound I to the pharmaceutically acceptable polymer is in general in the range of 1: 1 to 5: 95, or 1: 1 to 1: 9.
  • the ASD of Compound I comprises 5-40%w/w of Compound I and 60-95%w/w of HPMC-AS.
  • the ASD of Compound I comprises 10-40%w/w of Compound I and 60-90%w/w of HPMC-AS.
  • the ASD of Compound I comprises 5-30%w/w of Compound I and 70-95%w/w of HPMC-AS.
  • the ASD of Compound I comprises 10-30%w/w of Compound I and 70-90%w/w of HPMC-AS.
  • the ASD of Compound I comprises 5-25%w/w of Compound I and 75-95%w/w of HPMC-AS.
  • the ASD of Compound I comprises 10-25%w/w of Compound I and 75-90%w/w of HPMC-AS.
  • the ASD of Compound I comprises 5-20%w/w of Compound I and 80-95%w/w of HPMC-AS.
  • the ASD of Compound I comprises 10-20%w/w of Compound I and 80-90%w/w of HPMC-AS.
  • the ASD of Compound I comprises 10-40%w/w of Compound I and 60-90%w/w of PVP-VA.
  • the ASD of the present invention does not include any surfactant.
  • the ASD of the present invention may include a surfactant to enhance solubility and/or to improve physical stability.
  • a surfactant in general is in an amount of 5-40%w/w, preferably 10-30%w/w of the ASD.
  • a pharmaceutically acceptable surfactant useful as an additive in the solid dispersion may include polysorbate (e.g., polysorbate 20, polysorbate 40, polysorbate 80, polysorbate 85, polysorbate 60, etc. ) , cyclodextrin, polyoxyl 20 stearate, polyoxyl 35 castor oil, poloxamer, polyoxyethylene sorbitan monoisostearate, polyethylene glycol 40 sorbitan diisostearate, polyoxyl 40 hydrogenated castor oil, poloxamer 331, polyoxyethylene fatty acid esters, polyoxyl 40 castor oil, poloxamer 188, polyoxyethylene polyoxypropylene 1800, oleic acid, sodium desoxycholate, sodium lauryl sulfate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan trioleate, N-carbamoyl methoxypolyethylene glycol 2000-1, 2-distearol, myristic acid,
  • the physical state of the ASD is analyzed with an X-ray powder diffractometer (XRPD) .
  • XRPD X-ray powder diffractometer
  • thermochemical property of the ASD is analyzed with a differential scanning calorimeter (DSC) .
  • DSC differential scanning calorimeter
  • the results show that the ASD of Compound I has only one glass transition temperature and does not show any endothermic peak (melting peak) , which confirms Compound I being amorphous in ASD.
  • the resulting ASD can be formulated into pharmaceutical compositions that exhibit high bioavailability.
  • the ASD of the present invention provides a better solubility when dissolved in a pH 6.8 phosphate buffer than Type A crystalline.
  • the ASD of the present invention is stable and remains as amorphous for at least one month at 25-40°C in 60-75%relative humidity.
  • the ASD of the present invention is chemically stable and exhibits no significant purity change when stored at 25-40°C in 60-75%relative humidity for at least one month.
  • the ASD of the present invention may be prepared via spray drying, hot melt extrusion, or lyophilization technique.
  • the solid matrix has Compound I finely dispersed (molecular dispersion) in such a way that the solubility of the compound is maximized, thereby improving the bioavailability of the compound.
  • the ASD of the present invention is prepared by dissolving Compound I in a sufficient amount of an organic solvent and mixing the resulting solution with a solution containing a pharmaceutically acceptable carrier and optionally a solubility enhancer such as a surfactant, resulting in a spray solution.
  • the solvent may then be evaporated off, leaving the drug dispersed/dissolved in the matrix.
  • the method comprises the steps of: (a) dissolving Compound I and a pharmaceutically acceptable carrier in a solvent; and (b) drying the solution obtained in step (a) .
  • step (a) comprises: dissolving Compound I in a sufficient amount of an organic solvent; dissolving a pharmaceutically acceptable carrier in a solvent; and then mixing the two solutions.
  • organic solvents are used for dissolving Compound I and the carrier.
  • the organic solvents may include an alcohol, a haloalkane, acetone, acetic acid, ethyl acetate, N, N-dimethylformamide, DMSO, tetrahydrofuran, or a mixture thereof.
  • the alcohol is methanol, ethanol, propanol, or isopropanol.
  • the haloalkane is dichloromethane, chloroform, or carbon tetrachloride.
  • water or a mixture of water and an organic solvent is used for dissolving Compound I and the carrier.
  • step (b) comprises spray drying. In another embodiment, step (b) comprises spray drying in combination with a fluid bed. In a further embodiment, step (b) comprises evaporation of the solvent using a rotovap.
  • the solvent may be removed by evaporation via spray drying technique.
  • spray drying being used conventionally and broadly refers to processes involving breaking up liquid mixture into small droplets (atomization) and rapidly removing solvent from the mixture in a spray-drying apparatus (e.g., a nozzle) where there is a strong driving force for evaporation of solvent from the droplets.
  • the feed liquid may be a solution, slurry, emulsion, gel or paste, provided that it is pumpable and capable of being atomized.
  • Spray-drying processes and spray-drying equipment are described generally in Perry's Chemical Engineers'Handbook, pages 20-54 to 20-57 (Sixth Edition, 1984) .
  • the driving force for solvent elimination or evaporation is usually provided by keeping the partial pressure of solvent in the spray-drying equipment substantially below the vapor pressure of the solvent at the temperature of the drying droplets.
  • the ASD is prepared by hot-melt extrusion.
  • Compound I and a carrier are first mixed uniformly.
  • the mixture is fed to an extruder and extruded at a higher temperature than the melting temperature of the mixture of Compound I and the carrier.
  • the collected solid is grinded and passed through a mesh filter to produce the ASD powder.
  • the present invention is also directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of Compound I in an ASD form and pharmaceutically acceptable excipient (s) .
  • compositions which are inactive ingredients, can be selected by those skilled in the art using conventional criteria.
  • Pharmaceutically acceptable excipients include, but are not limited to, non-aqueous based solutions, suspensions, emulsions, microemulsions, micellar solutions, gels, and ointments.
  • the pharmaceutically acceptable excipients may also contain ingredients that include, but are not limited to, saline and aqueous electrolyte solutions; ionic and nonionic osmotic agents such as sodium chloride, potassium chloride, glycerol, and dextrose; pH adjusters and buffers such as salts of hydroxide, phosphate, citrate, acetate, borate, and trolamine; antioxidants such as salts, acids and/or bases of bisulfite, sulfite, metabisulfite, thiosulfite, ascorbic acid, acetyl cysteine, cysteine, glutathione, butylated hydroxyanisole, butylated hydroxytoluene, tocopherols, and ascorbyl palmitate; surfactants such as lecithin, phospholipids, including but not limited to phosphatidylcholine, phosphatidylethanolamine and phosphatidyl inositol; po
  • Such pharmaceutically acceptable excipients may be preserved against bacterial contamination using well-known preservatives, these include, but are not limited to, benzalkonium chloride, ethylene diamine tetra-acetic acid and its salts, benzethonium chloride, chlorhexidine, chlorobutanol, methylparaben, thimerosal, and phenylethyl alcohol, or may be formulated as a non-preserved formulation for either single or multiple use.
  • a tablet or a capsule formulation comprising Compound I may contain other excipients that have no bioactivity and no reaction with the active compound.
  • Excipients of a tablet may include fillers, binders, lubricants and glidants, disintegrators, wetting agents, and release rate modifiers.
  • Binders promote the adhesion of particles of the formulation and are important for a tablet formulation. Examples of binders include, but not limited to, carboxymethylcellulose, cellulose, ethylcellulose, hydroxypropylmethylcellulose, methylcellulose, karaya gum, starch, and tragacanth gum, poly (acrylic acid) , and polyvinylpyrrolidone.
  • composition is tableted.
  • a tablet formulation comprises ASD of the present invention in a weight range of 5-75%, preferably 5-40%.
  • a tablet formulation comprises one or more fillers, for example lactose and/or microcrystalline cellulose, in a total weight percent range of 10-80%, preferably 20-80%or 40-80%.
  • a tablet formulation comprises a disintegrant in a weight percentage of 4-20%, preferably 5-15%.
  • a tablet formulation comprises a glidant, in a weight percent range of 0.5-10%, preferably 1-5%.
  • a tablet formulation comprises a lubricant, for example, magnesium stearate, in a weight percent range of 0.25-2.0%, preferably 0.25-1.0%, and more preferably 0.5-1.0%.
  • Compound I was prepared according to the procedures described in Example 21 of WO2018/049781. Compound I was first dissolved in a mixed solvent of acetone and deionized water (4: 1 v/v) by heating to 50°C and the temperature of the resulting solution was then decreased to 30°C, followed by addition of crystal seed. The temperature of the mixture was further lowered to 20-25°C for precipitation. The solid was filtered and washed with a mixed solvent of acetone/water (2: 3 v/v) to provide Type A crystalline.
  • HPMCAS-10-SDD (10%drug loading) 2.00 g of Compound I was dissolved in 360 mL of methanol/acetone (4: 6 v/v) . While stirring at 100 rpm, 18.00 g of HPMC-AS was added slowly. After addition, stirring was continued for 2 hours until a clear solution was obtained. The solution was then placed in a Yamato ADL 311S spray-dryer for ASD preparation which was set with inlet temperature of 80°C, outlet temperature of 46-52°C, flow-rate of 5.2-11.3 mL/min and spray air pressure of 0.1 MPa. The collected spray-dried material was transferred to a glass dish, covered and vacuum-dried for 2 hours to give 15.06 g ASD powder.
  • Table 2 show four ASDs prepared according to the above-described procedure with different amounts of Compound I and reagents.
  • PVPVA-10-HME (10%drug loading) 2.00 g of Compound I and 18.00 g of PVP-VA were mixed uniformly. After passing through a 40-mesh filter, the mixture was fed to a Thermo MiniCTW extruder for ASD preparation at 20 rpm under 160°C. The collected yellow solid was grinded and passed through a 40-mesh filter to give 11.35 g ASD powder. The extrusion was carried out at 30 rpm under 180°C.
  • PVPVA-20-HME (20%drug loading) and PVPVA-40-HME (40%drug loading) were prepared similarly with different amounts of PVP-VA (see Table 3) .
  • Phosphate buffer pH 6.8 : 3.40 g of potassium dihydrogen phosphate and 0.45 g of sodium hydroxide were dissolved in 500 mL of water.
  • Type A About 8.0 mg of Type A sample was added to 20 mL of the phosphate buffer (pH 6.8) in a 30-mL glass vial. The vial was capped, placed in a shaker, and kept shaking with 150 rpm at 37°C. At indicated time intervals (10, 30, 60, 120, 240 min) , a fraction of the suspension was removed and filtered through a 0.45- ⁇ m filter by discarding the first part of the filtrate. The filtrate was diluted and then analyzed by HPLC. The results (averaged from three repeats) are shown in Table 2 and FIG. 1.
  • ASD An appropriate amount of ASD (about 3.0 mg of Compound I) was added to 7.5 mL of the phosphate buffer (pH 6.8) in a 30-mL glass vial. The vial was capped, placed in a shaker, and kept shaking with 150 rpm at 37°C. At indicated time intervals (10, 30, 60, 120, 240 min) , a fraction of the suspension was removed and centrifuged at 12,000 rpm for 5 minutes to give a clear solution that was then analyzed by HPLC. The results (averaged from three repeats) are shown in Table 4 and FIG. 1.
  • Type A Accurately weighted Type A sample (2 ⁇ 5 mg) was placed in a DSC pan which was then sealed and placed in TA Instruments Q2000. The pan was heated from room temperature to 230°C at a rate of 20°C/min and after 5 min, rapidly cooled to 0°C at a rate of 50°C/min. After another 5 min, the DSC analysis was carried out between 0 to 210°C at a rate of 10°C/min.
  • Tg glass transition temperatures
  • ASD Accurately weighted ASD sample (2 ⁇ 5 mg) was placed in a DSC pan which was then sealed and placed in TA Instruments Q2000. The pan was heated from room temperature to 135°C at a rate of 20°C/min and after 5 minutes, rapidly cooled to 0°C at a rate of 50°C/min. After another 5 min, the DSC analysis was carried out between 0 to 210°Cat a rate of 10°C/min (FIG. 2 and FIG. 3) .
  • the glass transition temperatures (Tg) are summarized in Table 5.
  • the ASDs of HPMCAS-10-SDD and PVPVA-10-HME were transferred to brown glass vials uncapped respectively, which were then placed inside desiccators to investigate the hygroscopicity.
  • the desiccators contained a saturated potassium nitrate solution at the bottom to maintain 92.5%relative humidity (RH) .
  • the ASDs were weighed after 0 and 10 days and inspected for their appearances. The weights increases were calculated as shown in Table 6. After 10 days under the high humidity condition, HPMCAS-10-SDD solid dispersion remained as a while or almost white powder, without obvious change in the appearance, and had low degrees of hygroscopicity.
  • PVPVA-10-HME solid dispersion had certain appearance change from an almost white powder to transparent semi-solid and significant weigh increase due to moisture absorption, indicating its high hygroscopicity, which is related to high hygroscopic nature of the carrier PVP-VA.
  • Capped brown glass vials each containing an ASD sample (HPMCAS-10-SDD and PVPVA-10-HME) were placed inside stability chambers. After 11 and 30 days under 25°C/60%RH and 40°C/75%RH, the samples were evaluated by XRPD, DSC, solubility, and relative substances, respectively.
  • the XRPD diagrams of HPMCAS-10-SDD after stored under (A) 25°C/60%RH, sealed and (B) 40°C/75%RH, sealed for 0-30 days are shown in FIG. 6.
  • the XRPD diagrams of PVPVA-10-HME stored under 25°C/60%RH, sealed for 0-30 days are shown in FIG. 7.
  • the results show that there is no observed crystalline diffraction peak in the ASD samples, indicating that the ASD samples remain as amorphous at least for 30 days.
  • Type A and HPMCAS-10-SDD were formulated with excipients, respectively.
  • the PK properties of two formulations administered orally in beagle dogs were evaluated. Each formulation was tested in three dogs, each weighed 8 ⁇ 12 kg.
  • a formulation was prepared by wet granulation. Firstly, mannitol, pregelatinized starch, sodium carboxymethyl starch and sodium dodecyl sulfate of different amounts were mixed evenly according to Table 8. Secondly, Type A and Povidone K30 were added into an appropriate amount of absolute alcohol, stirred, and mixed as adhesive. Finally, the adhesive was added to the evenly mixed excipients, followed by granulation, drying, addition of magnesium stearate, and mixing into a powder.
  • Composition Amount (mg) Drug substance (Type A) 5 mannitol 265 Pregelatinized starch 56.25 Sodium carboxymethyl starch 30 Sodium dodecyl sulfate 7.5 Povidone K30 7.5 Absolute alcohol ⁇ 0.06 mL Magnesium stearate 3.75 Total 375
  • a formulation was prepared by dry granulation. HPMCAS-10-SDD, mannitol, microcrystalline cellulose, different amounts of pregelatinized starch and silicon dioxide were mixed evenly according to Table 9, followed by dry granulation, addition of magnesium stearate, and tableting.
  • composition Amount/tablet (mg) HPMCAS-10-SDD 80 Mannitol 482 Microcrystalline cellulose 96 Pregelatinized starch 120 Silicon dioxide 16 Magnesium stearate 6 Total 800
  • HPMCAS-10-SDD has better C max and AUC in beagle dogs than Type A.

Abstract

The present invention provides an amorphous solid dispersion comprises (S) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1H-pyrazole-4-carboxamide (Compound I) and a pharmaceutically acceptable polymer, and a pharmaceutical composition comprising the amorphous solid dispersion. The amorphous solid dispersion of the present invention is stable upon storage and provides better solubility and bioavailability when comparing with a crystalline form.

Description

AMORPHOUS SOLID DISPERSION COMPRISING (S) -1- (1-ACRYLOYLPYRROLIDIN-3-YL) -3- ( (3, 5-DIMETHOXYPHENYL) ETHYNYL) -5- (METHYLAMINO) -1H-PYRAZOLE-4-CARBOXAMIDE
The present invention relates to amorphous solid dispersions of (S) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1H-pyrazole-4-carboxamide.
BACKGROUND OF THE INVENTION
(S) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1H-pyrazole-4-carboxamide (Compound I) is a potent inhibitor of fibroblast growth factor receptors (FGFR) . The preparation of Compound I and its use in the treatment of cancers are described in WO2018/049781, which is incorporated herein by reference in its entirety.
DESCRIPTION OF THE DRAWING
FIG. 1 shows the solubility profiles of Type A and ASD in a pH 6.8 phosphate buffer (n=3) .
FIG. 2 shows the DSC diagrams of amorphous solid dispersions made via spray drying.
FIG. 3 shows the DSC diagrams of amorphous solid dispersions made via hot melt extrusion.
FIG. 4 shows the XRPD diagrams of Type A and amorphous solid dispersions (HPMCAS) via made by spray drying.
FIG. 5 shows the XRPD diagrams of Type A and amorphous solid dispersions (PVPVA) made via hot melt extrusion.
FIG. 6 shows the XRPD diagrams of HPMCAS-10-SDD after storage under (A) 25℃/60%RH, sealed and (B) 40℃/75%RH, sealed.
FIG. 7 shows the XRPD diagrams of PVPVA-10-HME after storage under 25℃/60%RH, sealed.
FIG. 8 shows the DSC diagrams of HPMCAS-10-SDD after storage under (A) 25℃/60%RH, sealed and (B) 40℃/75%RH, sealed.
FIG. 9 shows the DSC diagrams of PVPVA-10-HME after storage under 25℃/60%RH, sealed. FIG. 10 shows the solubility profiles of HPMCAS-10-SDD after storage under (A) 25℃/60%RH, sealed and (B) 40℃/75%RH, sealed.
FIG. 11 shows the solubility profiles of PVPVA-10-HME after storage under 25℃/60%RH, sealed.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to an amorphous solid dispersion (ASD) comprising (S) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1H-pyrazole-4-carboxamide (Compound I) , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable polymer.
Figure PCTCN2022128315-appb-000001
The present invention discloses that the ASD form of Compound I has advantages over the crystalline form for use in preparing drug formulations. The ASD form of Compound I has good solubility and bioavailability, and is chemically and physically stable.
Type A Crystalline Form
Type A crystalline form is prepared from Compound I as described in WO2018/049781. Type A crystalline form can be prepared by dissolving Compound I in acetone/water, followed by precipitation at a lower temperature.
The X-ray powder diffraction (XRPD) data of Type A are shown in Table 1.
Table 1
2-theta d spacing Intensity (%)
6.66 13.26 19.2
8.69 10.17 0.6
10.05 8.79 16.3
10.96 8.06 33.9
12.62 7.01 0.8
13.29 6.65 5.1
13.99 6.33 40.8
14.55 6.08 0.5
15.71 5.64 14.3
16.14 5.49 17.1
17.42 5.09 67.0
17.82 4.97 41.1
18.36 4.83 4.0
19.90 4.46 17.6
20.29 4.37 3.1
20.63 4.30 3.3
21.58 4.11 10.9
22.14 4.01 100.0
22.85 3.89 16.2
23.40 3.80 18.7
24.07 3.69 29.8
24.91 3.57 22.9
25.43 3.50 4.1
26.37 3.38 5.0
26.74 3.33 7.2
27.48 3.24 4.9
28.28 3.15 55.5
29.74 3.00 2.3
30.50 2.93 10.3
31.86 2.81 6.0
32.35 2.77 4.6
33.27 2.69 1.3
33.88 2.64 3.4
34.53 2.60 3.6
35.17 2.55 8.2
35.55 2.52 1.8
36.04 2.49 1.4
36.61 2.45 2.2
36.83 2.44 2.0
37.51 2.40 1.8
38.64 2.33 5.9
Type A of the present invention has a solubility of 6.4 μg/mL after equilibrium in water at room temperature for 24 hours.
Amorphous Solid Dispersion
The ASD of Compound I comprises Compound I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable polymer. The ASD of Compound I is stable in an amorphous form in a solid state for extended periods of time that may be used for preparing drug formulations. The ASD of Compound I has a desirable pharmaceutical profile, and it is amenable to manufacturing.
A pharmaceutically acceptable polymer is included in ASD to stabilize the compound and the dispersion, which may be a hydrophilic polymer, including cellulose based polymers  (e.g., hydroxypropylmethyl cellulose (HPMC, hypromellose) , ethyl cellulose, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hypromellose phthalate (HPMCP) , cellulose acetate, cellulose acetate phthalate, methyl cellulose, cellulose, carboxymethyl cellulose, microcrystalline cellulose, silicified microcrystalline cellulose, etc. ) , starch based polymers (e.g., hydroxypropyl starch, starches (including starches from any source, such as corn, potato, rice, wheat, which can be fully pregelatinized and partially gelatinized) ) , polyethylene glycol, polyacrylic acid, polyacrylamide, polyethylene oxide, polyvinylpyrrolidone, polyvinylalcohol, polyglycolized glycerides, polymethacrylates, hydrocolloids (e.g., carrageenan, chitosan, alginic acid, hyaluronic acid, pectinic acid, etc. ) .
Preferred polymers of the present invention include hydroxypropylmethylcellulose-acetate succinate (HPMC-AS) , polyvinylpyrrolidone-vinyl acetate copolymer (PVP-VA) , polyvinylpyrrolidone (PVP) , and hydroxypropylmethylcellulose (HPMC) . HPMC-AS and PVP-VA are further preferred.
The amount of Compound I in ASD is in general 5-60%, or 5-50%, 5-40%, 10-50%, or 10-40%by weight. For example, the amount of Compound I in ASD (drug loading) is 10%or 20%by weight.
The weight ratio of Compound I to the pharmaceutically acceptable polymer (e.g., HPMC-AS or PVP-VA) is in general in the range of 1: 1 to 5: 95, or 1: 1 to 1: 9.
For example, the ASD of Compound I comprises 5-40%w/w of Compound I and 60-95%w/w of HPMC-AS.
For example, the ASD of Compound I comprises 10-40%w/w of Compound I and 60-90%w/w of HPMC-AS.
For example, the ASD of Compound I comprises 5-30%w/w of Compound I and 70-95%w/w of HPMC-AS.
For example, the ASD of Compound I comprises 10-30%w/w of Compound I and 70-90%w/w of HPMC-AS.
For example, the ASD of Compound I comprises 5-25%w/w of Compound I and 75-95%w/w of HPMC-AS.
For example, the ASD of Compound I comprises 10-25%w/w of Compound I and 75-90%w/w of HPMC-AS.
For example, the ASD of Compound I comprises 5-20%w/w of Compound I and 80-95%w/w of HPMC-AS.
For example, the ASD of Compound I comprises 10-20%w/w of Compound I and  80-90%w/w of HPMC-AS.
For example, the ASD of Compound I comprises 10-40%w/w of Compound I and 60-90%w/w of PVP-VA.
In one preferred embodiment, the ASD of the present invention does not include any surfactant.
In another embodiment, the ASD of the present invention may include a surfactant to enhance solubility and/or to improve physical stability. A surfactant in general is in an amount of 5-40%w/w, preferably 10-30%w/w of the ASD.
A pharmaceutically acceptable surfactant useful as an additive in the solid dispersion may include polysorbate (e.g., polysorbate 20, polysorbate 40, polysorbate 80, polysorbate 85, polysorbate 60, etc. ) , cyclodextrin, polyoxyl 20 stearate, polyoxyl 35 castor oil, poloxamer, polyoxyethylene sorbitan monoisostearate, polyethylene glycol 40 sorbitan diisostearate, polyoxyl 40 hydrogenated castor oil, poloxamer 331, polyoxyethylene fatty acid esters, polyoxyl 40 castor oil, poloxamer 188, polyoxyethylene polyoxypropylene 1800, oleic acid, sodium desoxycholate, sodium lauryl sulfate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan trioleate, N-carbamoyl methoxypolyethylene glycol 2000-1, 2-distearol, myristic acid, steareth, stearic acid, polyoxyl 40 stearate, polyoxyl 60 stearate, sucrose stearate, tocopherol, polyoxyl castor oil, triglyceride synthetic, trimyristin, tristearin, magnesium stearate, lecithin, lauryl sulfate, vitamin E, egg yolk phosphatides, docusate sodium, dimyristoyl phosphatidylglycerol, dimyristoyl lecithin, Capryol 90 (propylene glycol monocaprylate) , Capryol PGMC (propylene glycol monocaprylate) , deoxycholate, cholesterol, Cremophor EL, Propylene glycol alginate, Croval A-10 (PEG 60 almond glycerides) , Labrafil 1944 (oleoyl macrogol-6 glycerides) , Labrafil 2125 (linoleoyl macrogol-6 glycerides) , Labrasol (caprylocaproyl macrogol-8 glycerides) , Lauroglycol 90 (propylene glycol monolaurate) , Lauroglycol FCC (propylene glycol laurate) , calcium stearate, Lecithin Centromix E, Lecithin Centrophase 152, Lecithin Centrol 3F21B, POE 26 glycerin, Olepal isosteariques (PEG-6 isostearate) , Plurol diisostearique (polyglycerol-3-diisostearate) , Plurol Oleique CC, POE 20 Sorbitan trioleate, Tagat TO (polyoxyethylene glycerol trioleate) , or Solutol (Macrogol-15 hydroxystearate) , or a mixture thereof.
The physical state of the ASD is analyzed with an X-ray powder diffractometer (XRPD) . The results show that the ASD of Compound I does not have a crystalline form peak, which confirms Compound I being amorphous in ASD.
The thermochemical property of the ASD is analyzed with a differential scanning  calorimeter (DSC) . The results show that the ASD of Compound I has only one glass transition temperature and does not show any endothermic peak (melting peak) , which confirms Compound I being amorphous in ASD. The resulting ASD can be formulated into pharmaceutical compositions that exhibit high bioavailability.
The ASD of the present invention provides a better solubility when dissolved in a pH 6.8 phosphate buffer than Type A crystalline.
The ASD of the present invention is stable and remains as amorphous for at least one month at 25-40℃ in 60-75%relative humidity.
In one embodiment, the ASD of the present invention is chemically stable and exhibits no significant purity change when stored at 25-40℃ in 60-75%relative humidity for at least one month.
Methods for Preparing ASD
The ASD of the present invention may be prepared via spray drying, hot melt extrusion, or lyophilization technique.
The solid matrix has Compound I finely dispersed (molecular dispersion) in such a way that the solubility of the compound is maximized, thereby improving the bioavailability of the compound.
In one embodiment, the ASD of the present invention is prepared by dissolving Compound I in a sufficient amount of an organic solvent and mixing the resulting solution with a solution containing a pharmaceutically acceptable carrier and optionally a solubility enhancer such as a surfactant, resulting in a spray solution. The solvent may then be evaporated off, leaving the drug dispersed/dissolved in the matrix.
In one embodiment, the method comprises the steps of: (a) dissolving Compound I and a pharmaceutically acceptable carrier in a solvent; and (b) drying the solution obtained in step (a) .
In one embodiment, step (a) comprises: dissolving Compound I in a sufficient amount of an organic solvent; dissolving a pharmaceutically acceptable carrier in a solvent; and then mixing the two solutions.
In one embodiment, organic solvents are used for dissolving Compound I and the carrier. The organic solvents may include an alcohol, a haloalkane, acetone, acetic acid, ethyl acetate, N, N-dimethylformamide, DMSO, tetrahydrofuran, or a mixture thereof. For example, the alcohol is methanol, ethanol, propanol, or isopropanol. For example, the haloalkane is  dichloromethane, chloroform, or carbon tetrachloride.
In one embodiment, water or a mixture of water and an organic solvent is used for dissolving Compound I and the carrier.
In one embodiment, step (b) comprises spray drying. In another embodiment, step (b) comprises spray drying in combination with a fluid bed. In a further embodiment, step (b) comprises evaporation of the solvent using a rotovap.
In one embodiment, the solvent may be removed by evaporation via spray drying technique. The term "spray drying" being used conventionally and broadly refers to processes involving breaking up liquid mixture into small droplets (atomization) and rapidly removing solvent from the mixture in a spray-drying apparatus (e.g., a nozzle) where there is a strong driving force for evaporation of solvent from the droplets. In a typical spray drying process, the feed liquid may be a solution, slurry, emulsion, gel or paste, provided that it is pumpable and capable of being atomized.
Spray-drying processes and spray-drying equipment are described generally in Perry's Chemical Engineers'Handbook, pages 20-54 to 20-57 (Sixth Edition, 1984) . The driving force for solvent elimination or evaporation is usually provided by keeping the partial pressure of solvent in the spray-drying equipment substantially below the vapor pressure of the solvent at the temperature of the drying droplets.
Once spraying is over, the feed and atomization are stopped, and the resulting solid dispersion is collected and vacuum-dried further if necessary in an oven at about 40-60℃.
In one embodiment, the ASD is prepared by hot-melt extrusion. In this method, Compound I and a carrier are first mixed uniformly. The mixture is fed to an extruder and extruded at a higher temperature than the melting temperature of the mixture of Compound I and the carrier. The collected solid is grinded and passed through a mesh filter to produce the ASD powder.
Pharmaceutical Compositions
The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of Compound I in an ASD form and pharmaceutically acceptable excipient (s) .
Pharmaceutically acceptable excipients, which are inactive ingredients, can be selected by those skilled in the art using conventional criteria. Pharmaceutically acceptable excipients include, but are not limited to, non-aqueous based solutions, suspensions,  emulsions, microemulsions, micellar solutions, gels, and ointments. The pharmaceutically acceptable excipients may also contain ingredients that include, but are not limited to, saline and aqueous electrolyte solutions; ionic and nonionic osmotic agents such as sodium chloride, potassium chloride, glycerol, and dextrose; pH adjusters and buffers such as salts of hydroxide, phosphate, citrate, acetate, borate, and trolamine; antioxidants such as salts, acids and/or bases of bisulfite, sulfite, metabisulfite, thiosulfite, ascorbic acid, acetyl cysteine, cysteine, glutathione, butylated hydroxyanisole, butylated hydroxytoluene, tocopherols, and ascorbyl palmitate; surfactants such as lecithin, phospholipids, including but not limited to phosphatidylcholine, phosphatidylethanolamine and phosphatidyl inositol; poloxamers and poloxamines, polysorbates such as polysorbate 80, polysorbate 60, and polysorbate 20, polyethers such as polyethylene glycols and polypropylene glycols; polyvinyls such as polyvinyl alcohol and povidone; cellulose derivatives such as methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose and hydroxypropyl methylcellulose and their salts; petroleum derivatives such as mineral oil and white petrolatum; fats such as lanolin, peanut oil, palm oil, soybean oil; mono-, di-, and triglycerides; polymers of acrylic acid such as carboxypolymethylene gel, and hydrophobically modified cross-linked acrylate copolymer; polysaccharides such as dextrans and glycosaminoglycans such as sodium hyaluronate. Such pharmaceutically acceptable excipients may be preserved against bacterial contamination using well-known preservatives, these include, but are not limited to, benzalkonium chloride, ethylene diamine tetra-acetic acid and its salts, benzethonium chloride, chlorhexidine, chlorobutanol, methylparaben, thimerosal, and phenylethyl alcohol, or may be formulated as a non-preserved formulation for either single or multiple use.
For example, a tablet or a capsule formulation comprising Compound I may contain other excipients that have no bioactivity and no reaction with the active compound. Excipients of a tablet may include fillers, binders, lubricants and glidants, disintegrators, wetting agents, and release rate modifiers. Binders promote the adhesion of particles of the formulation and are important for a tablet formulation. Examples of binders include, but not limited to, carboxymethylcellulose, cellulose, ethylcellulose, hydroxypropylmethylcellulose, methylcellulose, karaya gum, starch, and tragacanth gum, poly (acrylic acid) , and polyvinylpyrrolidone.
In one embodiment the composition is tableted.
In one embodiment, a tablet formulation comprises ASD of the present invention in a  weight range of 5-75%, preferably 5-40%.
In one embodiment, a tablet formulation comprises one or more fillers, for example lactose and/or microcrystalline cellulose, in a total weight percent range of 10-80%, preferably 20-80%or 40-80%.
In one embodiment, a tablet formulation comprises a disintegrant in a weight percentage of 4-20%, preferably 5-15%.
In one embodiment, a tablet formulation comprises a glidant, in a weight percent range of 0.5-10%, preferably 1-5%. In one embodiment, a tablet formulation comprises a lubricant, for example, magnesium stearate, in a weight percent range of 0.25-2.0%, preferably 0.25-1.0%, and more preferably 0.5-1.0%.
The following examples further illustrate the present invention. These examples are intended merely to be illustrative of the present invention and are not to be construed as being limiting.
EXAMPLES
Example 1. Preparation of Type A Crystalline Form
Compound I was prepared according to the procedures described in Example 21 of WO2018/049781. Compound I was first dissolved in a mixed solvent of acetone and deionized water (4: 1 v/v) by heating to 50℃ and the temperature of the resulting solution was then decreased to 30℃, followed by addition of crystal seed. The temperature of the mixture was further lowered to 20-25℃ for precipitation. The solid was filtered and washed with a mixed solvent of acetone/water (2: 3 v/v) to provide Type A crystalline.
Example 2. Preparation of ASD via Spray Drying
HPMCAS-10-SDD (10%drug loading) : 2.00 g of Compound I was dissolved in 360 mL of methanol/acetone (4: 6 v/v) . While stirring at 100 rpm, 18.00 g of HPMC-AS was added slowly. After addition, stirring was continued for 2 hours until a clear solution was obtained. The solution was then placed in a Yamato ADL 311S spray-dryer for ASD preparation which was set with inlet temperature of 80℃, outlet temperature of 46-52℃, flow-rate of 5.2-11.3 mL/min and spray air pressure of 0.1 MPa. The collected spray-dried material was transferred to a glass dish, covered and vacuum-dried for 2 hours to give 15.06 g ASD powder.
Table 2 show four ASDs prepared according to the above-described procedure with  different amounts of Compound I and reagents.
Table 2.
Figure PCTCN2022128315-appb-000002
*Methanol and acetone were removed during ASD preparation.
Example 3. Preparation of ASD via Hot Melt Extrusion
PVPVA-10-HME (10%drug loading) : 2.00 g of Compound I and 18.00 g of PVP-VA were mixed uniformly. After passing through a 40-mesh filter, the mixture was fed to a Thermo MiniCTW extruder for ASD preparation at 20 rpm under 160℃. The collected yellow solid was grinded and passed through a 40-mesh filter to give 11.35 g ASD powder. The extrusion was carried out at 30 rpm under 180℃.
PVPVA-20-HME (20%drug loading) and PVPVA-40-HME (40%drug loading) were prepared similarly with different amounts of PVP-VA (see Table 3) .
Table 3.
Sample PVPVA-10-HME PVPVA-20-HME PVPVA-40-HME
Drug loading (%) 10 20 40
Compound I (g) 2.00 2.00 4.00
PVP-VA (g) 18.00 8.00 6.01
ASD (g) 11.35 5.16 5.05
Example 4. Solubility Profiles of Type A and ASD
Phosphate buffer (pH 6.8) : 3.40 g of potassium dihydrogen phosphate and 0.45 g of sodium hydroxide were dissolved in 500 mL of water.
Type A: About 8.0 mg of Type A sample was added to 20 mL of the phosphate buffer (pH 6.8) in a 30-mL glass vial. The vial was capped, placed in a shaker, and kept shaking with 150 rpm at 37℃. At indicated time intervals (10, 30, 60, 120, 240 min) , a fraction of the suspension was removed and filtered through a 0.45-μm filter by discarding the first part of the  filtrate. The filtrate was diluted and then analyzed by HPLC. The results (averaged from three repeats) are shown in Table 2 and FIG. 1.
ASD: An appropriate amount of ASD (about 3.0 mg of Compound I) was added to 7.5 mL of the phosphate buffer (pH 6.8) in a 30-mL glass vial. The vial was capped, placed in a shaker, and kept shaking with 150 rpm at 37℃. At indicated time intervals (10, 30, 60, 120, 240 min) , a fraction of the suspension was removed and centrifuged at 12,000 rpm for 5 minutes to give a clear solution that was then analyzed by HPLC. The results (averaged from three repeats) are shown in Table 4 and FIG. 1.
Table 4. Results of Solubilities of Type A and ASD in pH 6.8 Phosphate Buffer (n=3)
Figure PCTCN2022128315-appb-000003
The results show that solubility increased significantly after Type A was converted into ASD with HPMCAS or PVPVA. As the drug loading increased, the solubility of ASD decreased and the decrease is more pronounced for ASD with PVPVA prepared via hot melt extrusion.
Example 5. Glass Transition Temperature Determination
Type A: Accurately weighted Type A sample (2～5 mg) was placed in a DSC pan which was then sealed and placed in TA Instruments Q2000. The pan was heated from room temperature to 230℃ at a rate of 20℃/min and after 5 min, rapidly cooled to 0℃ at a rate of  50℃/min. After another 5 min, the DSC analysis was carried out between 0 to 210℃ at a rate of 10℃/min. The glass transition temperatures (Tg) are summarized in Table 3.
ASD: Accurately weighted ASD sample (2～5 mg) was placed in a DSC pan which was then sealed and placed in TA Instruments Q2000. The pan was heated from room temperature to 135℃ at a rate of 20℃/min and after 5 minutes, rapidly cooled to 0℃ at a rate of 50℃/min. After another 5 min, the DSC analysis was carried out between 0 to 210℃at a rate of 10℃/min (FIG. 2 and FIG. 3) . The glass transition temperatures (Tg) are summarized in Table 5.
Table 5. Results of Glass Transition Temperature
Figure PCTCN2022128315-appb-000004
DSC curves show that there is only one glass transition temperature without observed melting peak, indicating that Compound I exists in an amorphous state among carriers made by both techniques. When the percentage of drug loading increases from 10%to 40%, Tg decreases, therefore the risk of phase separation increases. It would be desirable to keep drug loading low to ensure physical stability.
Example 6. XRPD
About 10 mg of each Type A crystalline and ASD was each sprayed on a silicon chip for XRPD measurement under 40 mA current, 40 kV voltage, 5 ～ 40° 2θ, 0.0263° scanning step and 0.3282°/min scanning speed. The results are shown in FIG. 4 (HPMCAS) and FIG. 5 (PVPVA) . Compound I in the ASD prepared by either spray drying or hot melt extrusion was shown in an amorphous state. XRPD shows no crystal diffraction peak in ASD powder, but characteristic diffraction peaks in Type A crystalline.
Example 7. Hygroscopicity of ASD with 10%Drug Loading under High Humidity Condition
The ASDs of HPMCAS-10-SDD and PVPVA-10-HME were transferred to brown  glass vials uncapped respectively, which were then placed inside desiccators to investigate the hygroscopicity. The desiccators contained a saturated potassium nitrate solution at the bottom to maintain 92.5%relative humidity (RH) . The ASDs were weighed after 0 and 10 days and inspected for their appearances. The weights increases were calculated as shown in Table 6. After 10 days under the high humidity condition, HPMCAS-10-SDD solid dispersion remained as a while or almost white powder, without obvious change in the appearance, and had low degrees of hygroscopicity. On the contrary, PVPVA-10-HME solid dispersion had certain appearance change from an almost white powder to transparent semi-solid and significant weigh increase due to moisture absorption, indicating its high hygroscopicity, which is related to high hygroscopic nature of the carrier PVP-VA.
Table 6. Results of Weight Increase due to Moisture Absorption
Figure PCTCN2022128315-appb-000005
Example 8. Stability Assessment of ASD
Capped brown glass vials each containing an ASD sample (HPMCAS-10-SDD and PVPVA-10-HME) were placed inside stability chambers. After 11 and 30 days under 25℃/60%RH and 40℃/75%RH, the samples were evaluated by XRPD, DSC, solubility, and relative substances, respectively.
After stored under 40℃/75%RH for 11 and 30 days, the appearance of PVPVA-10-HME ASD changed significantly, from an almost white powder to transparent semi-solid glued to the inner wall of the brown bottle, which is not acceptable. The samples remained glued to the wall during shaking, therefore no sample was taken for measurement. HPMCAS-10-SDD ASD appeared normal after stored under the same condition for 11 and 30 days, further showing that HPMCAS-10-SDD had better physical and chemical stabilities, and met product specification.
1)  XRPD Results
The XRPD diagrams of HPMCAS-10-SDD after stored under (A) 25℃/60%RH, sealed and (B) 40℃/75%RH, sealed for 0-30 days are shown in FIG. 6. The XRPD diagrams of PVPVA-10-HME stored under 25℃/60%RH, sealed for 0-30 days are shown in FIG. 7. The results show that there is no observed crystalline diffraction peak in the ASD samples, indicating that the ASD samples remain as amorphous at least for 30 days.
2)  DSC Results
The DSC curves of HPMCAS-10-SDD after stored at (A) 25℃/60%RH, sealed and (B) 40℃/75%RH, sealed for 0-30 days are shown in FIG. 8. The results show that only one Tg is observed without extra melting peak, indicating that the ASD samples remain as amorphous at least for 30 days.
3)  Solubility Results
FIG. 10 shows the solubility curves of HPMCAS-10-SDD (in a pH 6.8 phosphate buffer medium, n=3) after stored under (A) 25℃/60%RH, sealed and (B) 40℃/75%RH, sealed for different time periods (0, 11 and 30 days) . FIG. 11 shows the solubility curves of PVPVA-10-HME (in a pH 6.8 phosphate buffer media, n=3) after stored under 25℃/60%RH, sealed for different time periods (0, 11, 30 days) . The results show that there is no obvious change in the solubility profiles for two ASD samples after stored under two conditions for 30 days.
4) Relative Substance Results
Relative substance evaluations of HPMCAS-10-SDD after stored under (A) 25℃/60%RH, sealed and (B) 40℃/75%RH, sealed, and PVPVA-10-HME after stored under 25℃/60%RH, sealed for different time periods (0, 11 and 30 days) are summarized in Table 7. The results show that there was no obvious change in relative substance for two ASD samples after stored under two conditions for 11 and 30 days; both sample had acceptable stability.
Table 7. Results of Relative Substances of HPMCAS-10-SDD and PVPVA-10-HME
Figure PCTCN2022128315-appb-000006
Example 9. In vivo PK
Type A and HPMCAS-10-SDD were formulated with excipients, respectively. The PK properties of two formulations administered orally in beagle dogs were evaluated. Each formulation was tested in three dogs, each weighed 8 ～ 12 kg.
1) In vivo PK Determination of Type A Formulation
A formulation was prepared by wet granulation. Firstly, mannitol, pregelatinized starch, sodium carboxymethyl starch and sodium dodecyl sulfate of different amounts were mixed evenly according to Table 8. Secondly, Type A and Povidone K30 were added into an appropriate amount of absolute alcohol, stirred, and mixed as adhesive. Finally, the adhesive was added to the evenly mixed excipients, followed by granulation, drying, addition of magnesium stearate, and mixing into a powder.
Table 8. The Formulation of Type A
Composition Amount (mg)
Drug substance (Type A) 5
mannitol 265
Pregelatinized starch 56.25
Sodium carboxymethyl starch 30
Sodium dodecyl sulfate 7.5
Povidone K30 7.5
Absolute alcohol ～0.06 mL
Magnesium stearate 3.75
Total 375
The above formulation was added to 0.5%methylcellulose (MC) to give a suspension containing 0.6 mg/mL of Compound I. The suspension was then orally administered to fasted beagle dogs at 5 mL/kg, which was equivalent to a dose of 3 mg/kg. Blood samples were  collected at 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose. Concentrations of Compound I were quantified by LC-MS/MS analysis using an API-4500 mass spectrometer. The PK parameters were calculated using WinNonlin and the results are summarized in Table 8.
2) In vivo PK Determination of HPMCAS-10-SDD Formulation
A formulation was prepared by dry granulation. HPMCAS-10-SDD, mannitol, microcrystalline cellulose, different amounts of pregelatinized starch and silicon dioxide were mixed evenly according to Table 9, followed by dry granulation, addition of magnesium stearate, and tableting.
Table 9. Formulation of HPMCAS-10-SDD
Composition Amount/tablet (mg)
HPMCAS-10-SDD 80
Mannitol 482
Microcrystalline cellulose 96
Pregelatinized starch 120
Silicon dioxide 16
Magnesium stearate 6
Total 800
Four tablets were orally administered to fasted beagle dogs at a dose of 3 mg/kg. Blood samples were collected at 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose. Concentrations of Compound I were quantified by LC-MS/MS analysis. The PK parameters were calculated using WinNonlin and the results are summarized in Table 10.
Table 10. In vivo Dog PK Results
Figure PCTCN2022128315-appb-000007
The results show that HPMCAS-10-SDD has better C max and AUC in beagle dogs than Type A.
It is to be understood that the foregoing describes preferred embodiments of the present invention and that modifications may be made therein without departing from the scope of the present invention as set forth in the claims.

Claims (7)

  1. An amorphous solid dispersion comprising 5-40%w/w of compound I or a pharmaceutically acceptable salt thereof, and 60-95%w/w of hydroxypropylmethylcellulose-acetate succinate (HPMC-AS)
    Figure PCTCN2022128315-appb-100001
  2. The amorphous solid dispersion according to claim 1, comprising 5-20 %w/w of compound I.
  3. The amorphous solid dispersion according to claim 1, comprising 10 %w/w of compound I.
  4. The amorphous solid dispersion according to claim 1, prepared by either spray-drying or hot-melt extrusion.
  5. A pharmaceutical composition comprising the amorphous solid dispersion according to claim 1 and a pharmaceutically acceptable carrier.
  6. The pharmaceutical composition of claim 5, in a tablet form or a capsule form.
  7. A method for preparing the amorphous solid dispersion of claim 1, comprising the steps:
    (a) dissolving compound I or a pharmaceutically acceptable salt thereof and HPMC-AS in an organic solvent to form a solution; and
    (b) spray-drying the solution to form the amorphous solid dispersion.
PCT/CN2022/128315 2021-11-03 2022-10-28 Amorphous solid dispersion comprising (s) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1h-pyrazole-4-carboxamide WO2023078179A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3235435A CA3235435A1 (en) 2021-11-03 2022-10-28 Amorphous solid dispersion comprising (s)-1-(1-acryloylpyrrolidin-3-yl)-3-((3,5-dimethoxyphenyl) ethynyl)-5-(methylamino)-1h-pyrazole-4-carboxamide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163275076P 2021-11-03 2021-11-03
US63/275,076 2021-11-03

Publications (1)

Publication Number Publication Date
WO2023078179A1 true WO2023078179A1 (en) 2023-05-11

Family

ID=86240647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/128315 WO2023078179A1 (en) 2021-11-03 2022-10-28 Amorphous solid dispersion comprising (s) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1h-pyrazole-4-carboxamide

Country Status (2)

Country Link
CA (1) CA3235435A1 (en)
WO (1) WO2023078179A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007129066A1 (en) * 2006-05-05 2007-11-15 Astex Therapeutics Limited 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer
WO2018049781A1 (en) * 2016-09-19 2018-03-22 北京天诚医药科技有限公司 Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof
WO2020208592A1 (en) * 2019-04-12 2020-10-15 Dr. Reddy’S Laboratories Limited Process for preparation of erdafitinib, its purification and amorphous solid dispersion
WO2021129565A1 (en) * 2019-12-26 2021-07-01 Beijing Innocare Pharma Tech Co., Ltd. Crystalline forms of (s) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1h-pyrazole-4-carboxamide
CN113490492A (en) * 2019-03-04 2021-10-08 日本烟草产业株式会社 Amorphous solid dispersion of pyrazolylamide compound

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007129066A1 (en) * 2006-05-05 2007-11-15 Astex Therapeutics Limited 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer
WO2018049781A1 (en) * 2016-09-19 2018-03-22 北京天诚医药科技有限公司 Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof
CN113490492A (en) * 2019-03-04 2021-10-08 日本烟草产业株式会社 Amorphous solid dispersion of pyrazolylamide compound
WO2020208592A1 (en) * 2019-04-12 2020-10-15 Dr. Reddy’S Laboratories Limited Process for preparation of erdafitinib, its purification and amorphous solid dispersion
WO2021129565A1 (en) * 2019-12-26 2021-07-01 Beijing Innocare Pharma Tech Co., Ltd. Crystalline forms of (s) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1h-pyrazole-4-carboxamide

Also Published As

Publication number Publication date
CA3235435A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
KR101454086B1 (en) Stabilized amorphous forms of imatinib mesylate
CN1207896A (en) Solid pharmaceutical dispersions with enhanced bioavailability
US8921416B2 (en) Dronedarone solid dispersion and preparation method thereof
KR20070062507A (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
WO2015152433A1 (en) Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
US20210369620A1 (en) Solid dosage forms with high active agent loading
JP2009544617A5 (en)
US10660963B2 (en) Pharmaceutical composition containing tacrolimus and preparation methods thereof
US10940135B2 (en) Paclitaxel pharmaceutical composition and pharmaceutical preparation thereof, preparation process and use thereof
US20210260050A1 (en) Amorphous solid dispersion comprising 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide
WO2023078179A1 (en) Amorphous solid dispersion comprising (s) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1h-pyrazole-4-carboxamide
CN102186474A (en) Uchida hiroshi [jp]; fukuda mamoru [jp]; aritomi seigo
KR101920628B1 (en) A pharmaceutical composition comprising angiotensin receptor blocker
JP2007504190A (en) 3-[(2-{[4- (Hexyloxycarbonylamino-imino-methyl) -phenylamino] -methyl} -1-methyl-1H-benzimidazol-5-carbonyl) -pyridin-2-yl-amino] -New oral dosage forms of ethyl propionate and their salts
KR100805675B1 (en) Pharmaceutical compositions comprising clopidogrel besylate and methods for preparing the same
CN115554292A (en) Pharmaceutical compositions and methods for reducing blood glucose and treating conditions associated with glucagon
WO2020234448A1 (en) Nanoparticles comprising enzalutamide
AU2012201613B2 (en) Stabilized amorphous forms of Imatinib mesylate
CN101422425A (en) Etretinate type medicine solid dispersion

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22889204

Country of ref document: EP

Kind code of ref document: A1